Advanced search

Johan Luthman is EVP & Head-Research & Development at H. Lundbeck A. In the past Dr. Luthman was Chief Executive Officer at GeNeuro SA (Switzerland) and Head-Neuroscience Research at Merck Serono GmbH. Dr. Luthman received an undergraduate degree from Karolinska Institutet.

Mr. Jan V.
Luthman is a Fund Manager at Liontrust Investment Partners LLP.
He joined Liontrust in April 2012, transferring from Walkers Crips Asset Managers (WCAM).
He joined WCAM in 2000.
He has over 18 years of experience in international corporate management.
Following a mid-life career change, he was in the first group to pass the Securities Association exam in Investment Analysis in 1987 and then entered fund management in 1988.
Mr. Luthman holds a degree in Civil Engineering.

Kristina Luthman is the founder of Oncopeptides AB, which was founded in 2000.
She is currently a Professor at the University of Gothenburg.

Desiree Luthman is currently the Vice President Global-Regulatory Affairs at GLOSEL Co., Ltd.
and the Vice President-Regulatory Affairs at Egetis Therapeutics AB.
Previously, she held positions such as Director-Global Regulatory Strategy & Science at Bristol Myers Squibb Co., Senior Regulatory Director at Sanofi SA, Vice President-Regulatory Affairs at Verona Pharma Plc, and Senior Vice President-Global Regulatory Affairs at Passage Bio, Inc. Dr. Luthman obtained her doctorate degree from Karolinska Institutet in 1988.

Gösta Christian Luthman is currently an Independent Director at Havsfrun Investment AB, a Director at Select Travel AB, a Director at Christian Luthman Advokatbyrå AB, and a Partner at Wistrand Advokatbyrå Stockholm KB.
In the past, he served as Chairman at Varsity Capital Group AB, Director at Mondial Asset Management AB, Director at Bird & Bird Advokat KB, Director at Bird & Bird Partners AB, Deputy Director at Bössviken Consulting AB, Director at Bird & Bird Service AB, Deputy Director at Operations Instrument AB, Director at Bird & Bird Administration AB, and Director at Bird & Bird AB.